Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11883759 | 0.81 | HTR2A (0.46) | HTR2AMTNR1AMTNR1B | |
| SCHEMBL6653008 | 0.76 | CYP1A2 (0.48) | HTR2ACYP1A2ANPEPHRH1TP53 | |
| SCHEMBL3800822 | 0.72 | CYP1A2 (0.48) | HTR2AMTNR1AMTNR1BCYP1A2ANPEP | |
| SCHEMBL20992176 | 0.72 | CYP1A2 (0.48) | HTR2ACYP1A2ANPEPHRH1TP53 | |
| SCHEMBL568436 | 0.72 | HTR2C (0.49) | HTR2AHTR2C | |
| SCHEMBL17050195 | 0.72 | ANPEP (0.55) | HTR2ACYP1A2ANPEPHRH1TP53 | |
| SCHEMBL19368260 | 0.71 | HTR2A (0.44) | HTR2ACYP1A2ANPEPHRH1TP53 | |
| SCHEMBL17031841 | 0.71 | CYP1A2 (0.43) | HTR2AMTNR1AMTNR1BCYP1A2ANPEP | |
| SCHEMBL11144393 | 0.71 | CYP1A2 (0.58) | HTR2ACYP1A2ANPEPHRH1HTR2C | |
| SCHEMBL5897623 | 0.70 | MEN1 (0.48) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | HTR2A 2456/4885MTNR1A 3436/4885MTNR1B 2265/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | HTR2A 4176/4885MTNR1A 3782/4885MTNR1B 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.